Active, not recruitingPhase 2NCT04340843

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Studying Chondrosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Mia Weiss, MD
Yale University Cancer Center LAO
Intervention
Belinostat(drug)
Enrollment
19 enrolled
Eligibility
18 years · All sexes
Timeline
20202027

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04340843 on ClinicalTrials.gov

Other trials for Chondrosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Chondrosarcoma

← Back to all trials